[{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cenerimod","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cenerimod","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Cenerimod","moa":"S1PR1","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Viatris"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Cenerimod","moa":"S1PR1","graph1":"Immunology","graph2":"Phase III","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Group Corporation \/ Viatris"}]

Find Clinical Drug Pipeline Developments & Deals for Cenerimod

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ICHH-25
                          Not Confirmed
                          ICHH-25
                          Not Confirmed

                          Details : Under the agreement, Viatris will hold the right of ACT-334441 (cenerimod) for the development and commercialization. It is a clinical-stage candidate evaluated for autoimmune diseases.

                          Product Name : ACT-334441

                          Product Type : Other Small Molecule

                          Upfront Cash : $10.0 million

                          February 27, 2025

                          Lead Product(s) : Cenerimod

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Viatris

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          ICHH-25
                          Not Confirmed
                          ICHH-25
                          Not Confirmed

                          Details : The collaboration aims for the global development and commercialization rights to ACT-246475 (selatogrel), a reversible, and selective 2-phenylprimdine-4-carboxamide and ACT-334441 (cenerimod).

                          Product Name : ACT-334441

                          Product Type : Other Small Molecule

                          Upfront Cash : $350.0 million

                          February 26, 2025

                          Lead Product(s) : Cenerimod

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Viatris

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          ICHH-25
                          Not Confirmed
                          ICHH-25
                          Not Confirmed

                          Details : ACT-334441 (cenerimod), is a highly selective S1P1 receptor modulator, being investigated as an oral once-daily tablet. Cenerimod potentially offers a novel approach for the treatment of SLE, a disease with a significant impact on patients and limited tr...

                          Product Name : ACT-334441

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 15, 2022

                          Lead Product(s) : Cenerimod

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          ICHH-25
                          Not Confirmed
                          ICHH-25
                          Not Confirmed

                          Details : Cenerimod 4 mg showed clinically meaningful improvement in mSLEDAI-2K primary efficacy endpoint and other measures of efficacy, consistent with the effect seen on biological activity. Cenerimod, novel S1P1 receptor modulator an oral treatment of systemic...

                          Product Name : ACT-334441

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 01, 2021

                          Lead Product(s) : Cenerimod

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank